Present status of statin therapy.
Statins are cardioprotective agents that reduce the adverse effects of increased low-density lipoprotein cholesterol (LDL-C) levels. For significantly dyslipidemic persons, who are at higher cardiovascular risk, combined statin therapy substantially reduces the mortality risk, thus potentially being an ideal risk-reducing combination with added risk reduction by lifestyle changes. Decisions regarding the initiation of statin therapy for primary prevention where the absolute risk reduction is much less are more difficult, involving LDL-C levels and higher C-reactive protein levels. For significantly dyslipidemic persons, combined intense exercise and statin therapy substantially reduces the mortality risk, thus potentially being an ideal risk-reducing combination.